|
Aug 8
|
Institutional owners may consider drastic measures as Moderna, Inc.'s (NASDAQ:MRNA) recent US$6.3b drop adds to long-term losses
|
|
Aug 8
|
15 Worst Performing Biotech Stocks in 2023
|
|
Aug 7
|
Moderna Weakens With No Bottom in Sight
|
|
Aug 7
|
Is Moderna (MRNA) a Potential Value Trap? A Deep Dive into the Financials
|